Search

Your search keyword '"Cazzola GA."' showing total 8 results
Start Over Author "Cazzola GA."
8 results on '"Cazzola GA."'

1. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency

Author

Quinti, I, Soresina, A, Spadaro, G, Martino, S, Donnanno, S, Agostini, C, Claudio, P, Franco, D, MARIA PESCE, A, Borghese, F, Guerra, A, Rondelli, R, Plebani, A, WITHIN THE IPINET ITALIAN PRIMARY IMMUNODEFICIENCY NETWORK IPINET DE MATTIA D, ITALIAN PRIMARY IMMUNODEFICIENCY N. E. T. W. O. R. K., Martire, B, Cossu, F, Schirilló, G, Castagnola, E, Pietrogrande, Mc, DELLE PIANE RM, Putti, C, Trizzino, A, Amato, Gm, Bertolini, P, Zecca, M, Consolini, Rita, Moschese, V, Rossi, P, Cancrini, C, Cazzola, Ga, and Verona

Published
2007

2. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study

Author

Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, Milito C, Trombetta AC, Visentini M, Martini H, Plebani A, Fiorilli M, IPINet Investigators, De Mattia D, Martire B, Cardinale F, Ranieri G, Silvestri F, Masi M, Cossu F, Anastasio E, Schillirò G, Matucci A, Vultaggio A, Aricò M, Pietrogrande MC, Delle Piane RM, Panisi C, Cambiaghi G, Pignata C, Putti MC, Trizzino A, Bertolini P, Consolini R, Ugazio AG, Duse M, Iacobini M, Moschese V, Cancrini C, Finocchi A, Pesce AM, Cagliuso M, Conti V, Granata G, Mitrevski M, Cecere F, Tovo PA, Martino S, Montin D, Nespoli L, Marinoni M, Pellegrini FP, Cazzola G.A., PESSION, ANDREA, Quinti., I, Soresina, A., Guerra, A., Rondelli, R., Spadaro, Giuseppe, Agostini, C., Milito, C., Trombetta, A. C., Visentini, M., Martini, H., Plebani, A., Fiorilli, M., De Mattia, D., Martire, B., Cardinale, F., Ranieri, G., Silvestri, F., Masi, M., Pession, A., Cossu, F., Anastasio, E., Schillirò, G., Matucci, A., Vultaggio, A., Aricò, M., Pietrogrande, M. C., Delle Piane, R. M., Panisi, C., Cambiaghi, G., Pignata, Claudio, Putti, M. C., Trizzino, A., Bertolini, P., Consolini, R., Ugazio, A. G., Duse, M., Iacobini, M., Moschese, V., Cancrini, C., Finocchi, A., Pesce, A. M., Cagliuso, M., Conti, V., Granata, G., Mitrevski, M., Cecere, F., Tovo, P. A., Martino, S., Montin, D., Nespoli, L., Marinoni, M., Pellegrini, F. P., Cazzola, G. A., Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, Milito C, Trombetta AC, Visentini M, Martini H, Plebani A, Fiorilli M, IPINet Investigator, De Mattia D, Martire B, Cardinale F, Ranieri G, Silvestri F, Masi M, Pession A, Cossu F, Anastasio E, Schillirò G, Matucci A, Vultaggio A, Aricò M, Pietrogrande MC, Delle Piane RM, Panisi C, Cambiaghi G, Pignata C, Putti MC, Trizzino A, Bertolini P, Consolini R, Ugazio AG, Duse M, Iacobini M, Moschese V, Cancrini C, Finocchi A, Pesce AM, Cagliuso M, Conti V, Granata G, Mitrevski M, Cecere F, Tovo PA, Martino S, Montin D, Nespoli L, Marinoni M, Pellegrini FP, and Cazzola GA.

Subjects
Male, bronchiectasis, X-linked agammaglobulinemia, Comorbidity, Gastroenterology, Immunoglobulin G, 0302 clinical medicine, Agammaglobulinemia, Risk Factors, Immunology and Allergy, Prospective Studies, Child, Prospective cohort study, 0303 health sciences, biology, Incidence, common variable immunodeficiency, Middle Aged, 3. Good health, Treatment Outcome, Italy, Female, Intravenous, Adult, x-linked agammaglobulinemia, medicine.medical_specialty, immunoglobulin replacement, Adolescent, effectiveness, iga, Immunology, Disease-Free Survival, Injections, Databases, 03 medical and health sciences, Immunoglobulin replacement, common variable immunodeficiency, X-linked agammaglobulinemia, bronchiectasis, IgA, effectiveness, Internal medicine, medicine, Humans, Risk factor, Preschool, Factual, Aged, 030304 developmental biology, Settore MED/38 - Pediatria Generale e Specialistica, Bronchiectasis, business.industry, Common variable immunodeficiency, Infant, Pneumonia, X-Linked, medicine.disease, Databases, Factual, Injections, Intravenous, Child, Preschool, Immunoglobulin A, Follow-Up Studies, Common Variable Immunodeficiency, Genes, X-Linked, Genes, biology.protein, Trough level, business, 030215 immunology
Abstract

A 5-years multicenter prospective study on 201 patients with common variable immunodeficiencies and 101 patients with X-linked agammaglobulinemia over a cumulative follow-up period of 1,365 patient-years was conducted to identify prognostic markers and risk factors for associated clinical co-morbidities, the effects of long-term immunoglobulin treatment and the IgG trough level to be maintained over time required to minimise infection risk. Overall, 21% of the patients with common variable immunodeficiencies and 24% of patients with X-linked agammaglobulinemia remained infection free during the study. A reduction of pneumonia episodes has been observed after initiation of Ig replacement. During the observation time, pneumonia incidence remained low and constant over time. Patients with pneumonia did not have significant lower IgG trough levels than patients without pneumonia, with the exception of patients whose IgG trough levels were persistently < 400 mg/dL. In X-linked agammaglobulinemia, the only co-morbidity risk factor identified for pneumonia by the final multivariable model was the presence of bronchiectasis. In common variable immunodeficiencies, our data allowed us to identify a clinical phenotype characterised by a high pneumonia risk: patients with low IgG and IgA levels at diagnosis; patients who had IgA level < 7 mg/dL and who had bronchiectasis. The effect of therapy with immunoglobulins at replacement dosage for non-infectious co-morbidities (autoimmunity, lymphocytic hyperplasia and enteropathy) remains to be established. A unique general protective trough IgG level in antibody deficiency patients will remain undefined because of the major role played by the progression of lung disease in X-linked agammaglobulinemia and in a subset of patients with common variable immunodeficiencies.

Published
2011

3. Risultati dell'applicazione delle raccomandazioni AIEOP per l'agammaglobulinemia X-recessiva

Author

Soresina A., Rondelli R., Notarangelo L.D., Duse M., Quinti I., Azzari C., pietrogrande M.C., Martino S., De Mattia D., Martire B., Rossi P., Moschese V., Cardinale F., Masi M., Pignata C., Amato G.M., Cazzola G.A., Consolini R., Nigro G., Stabile A., Locatelli F., Sciotto A., Di Nardo R., Strisciuglio P., Ambrosiani G., Marseglia G.L., Nespoli L., Felici P., Fiorini M., Ugazio A.G., Plebani A., PESSION, ANDREA, Soresina A., Rondelli R., Notarangelo LD., Duse M., Quinti I., Azzari C., pietrogrande MC., Martino S., De Mattia D., Martire B., Rossi P., Moschese V., Cardinale F., Masi M., Pignata C., Amato GM., Cazzola GA., Consolini R., Nigro G., Stabile A., Locatelli F., Sciotto A., Di Nardo R., Strisciuglio P., Ambrosiani G., Marseglia GL., Nespoli L., Felici P., Fiorini M., Pession A., Ugazio AG., and Plebani A.

Published
2005

5. [Neutrophil chemotaxis. II. Clinical implications and therapeutic indications in children].

Author

Cazzola GA, Valletta EA, and Cipolli M

Subjects
Adolescent, Cell Adhesion, Chediak-Higashi Syndrome physiopathology, Chemotactic Factors deficiency, Child, Child, Preschool, Ciliary Motility Disorders physiopathology, Hematologic Diseases therapy, Humans, Infant, Infant, Newborn, Neutropenia physiopathology, Neutrophils, Chemotaxis, Leukocyte
Abstract

Defects of neutrophil chemotaxis are usually accompanied by recurrent or chronic infections of the skin and the respiratory tract. The onset of clinical symptoms may occur early in infancy; infections tend to be severe and they are generally due by organisms which are of relatively low pathogenicity in the healthy subject. Abnormalities of neutrophil chemotaxis were classified and described as humoral, cellular and unclassified defects. The relevance of neutrophil chemotaxis in the single clinical entities was discussed, taking in particular account the most recent views on the argument. Some details on practical and theoretical therapeutic approaches were also reviewed.

Published
1990

7. [Neutrophil chemotaxis. I. Physiology aspects and study methods].

Author

Valletta EA, Cazzola GA, and Cipolli M

Subjects
Humans, Methods, Neutrophils physiology, Chemotaxis, Leukocyte physiology, Signal Transduction physiology
Abstract

Neutrophil chemotaxis is a complex orchestration of biochemical and morphologic events that requires the integrity and coordination of a complicated series of cellular functions. Different substances (both endogenous and exogenous) with chemotactic activity for human neutrophils were described; their interaction with specific receptors on neutrophil cell membrane is requested to induce a directional motility. The ligand-receptor interaction causes the activation of intracellular metabolic pathways and the modification of cytoskeletal structures involved in the chemotactic response. Neutrophil chemotaxis may be studied, for clinical purpose, by in vitro and in vivo methods. The two approaches of investigation are complementary, and, if properly used, they may give a valuable help in defining the nature of the chemotactic defect.

Published
1989

8. [Chronic suppurative bronchopathy and motility defect of neutrophils: evaluation of an immunomodulating treatment].

Author

Cazzola GA, Valletta EA, and Mastella G

Subjects
Adolescent, Adult, Child, Child, Preschool, Chronic Disease, Female, Humans, Levamisole analogs & derivatives, Neutrophils, Recurrence, Retrospective Studies, Bronchial Diseases therapy, Chemotaxis, Leukocyte drug effects, Levamisole therapeutic use
Abstract

Five patients with recurrent infections of the lower respiratory tract, chronic bronchial suppuration and significant defect of polymorphonuclear granulocyte (PMN) motility were studied. Clinical evaluation and in vitro studies of PMN motility were performed before, during and after the treatment with levamisole chlorhydrate (2.5 mg/Kg twice a week). Clinical improvement was obtained in all the patients, together with a significant increase in the chemotactic response of PMN. No side effects were reported. After a follow-up of 7-18 months PMN chemotaxis remained normal in all the patients and a reappearance of respiratory symptoms was observed only in one subject.

Published
1989

Catalog

Books, media, physical & digital resources
See catalog results